Article Versions Notes

Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, Wang Y, Wu J, Guo Y, Tully D, et al. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. Cells. 2019; 8(9):1010. https://doi.org/10.3390/cells8091010

Wen, Wei, Emily Marcinkowski, David Luyimbazi, Thehang Luu, Quanhua Xing, Jin Yan, Yujun Wang, Jun Wu, Yuming Guo, Dylan Tully, and et al. 2019. "Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer" Cells 8, no. 9: 1010. https://doi.org/10.3390/cells8091010

Wen, W., Marcinkowski, E., Luyimbazi, D., Luu, T., Xing, Q., Yan, J., Wang, Y., Wu, J., Guo, Y., Tully, D., Han, E. S., Yost, S. E., Yuan, Y., & Yim, J. H. (2019). Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. Cells, 8(9), 1010. https://doi.org/10.3390/cells8091010